title: Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
abstract: Genzyme Corp is developing tolevamer, an anionic toxin-binding polymer that binds and neutralizes the Clostridium difficile A and B toxins, for the potential treatment of C difficile-associated diarrhea (CDAD). Two phase III clinical trials of tolevamer in patients with CDAD have been completed and results from the second trial are expected to be released imminently.
authors.affiliation: Columbia University School of Medicine, St Luke's-Roosevelt Hospital Center, 10th Ave and 59th St, New York, NY 10025, USA. Scheinfeld@earthlink.net
authors.forename: Noah
authors.initials: N
authors.lastname: Scheinfeld
authors.forename: Kristen
authors.initials: K
authors.lastname: Biggers
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D016360:Clostridioides difficile / Q000187:drug effects; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010330:Patents as Topic; D011108:Polymers / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013451:Sulfonic Acids
chemical_list: D000900:Anti-Bacterial Agents; D011108:Polymers; D013451:Sulfonic Acids; C077114:styrenesulfonic acid polymer